11 results
8-K
EX-99.2
CHRS
Coherus Biosciences Inc
2 Feb 21
Entry into a Material Definitive Agreement
8:45am
the Hart-Scott Rodino Antitrust Improvements Act.
About Junshi Biosciences
Founded in December 2012, Junshi Biosciences (HK: 1877; SH: 688180 … , the risk that the parties are unable to obtain clearance under the Hart-Scott Rodino Antitrust Improvements Act, from the Committee on Foreign
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
2 Feb 21
Entry into a Material Definitive Agreement
8:45am
of $25 million per licensed compound per year.
Closing of the collaboration agreement is subject to clearance under the Hart-Scott Rodino Antitrust … that the parties are unable to obtain clearance under the Hart-Scott Rodino Antitrust Improvements Act, from the Committee on Foreign Investment in the United
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
22 Jan 24
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in Conference Call Information
8:01am
, including expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
Advisors
J.P. Morgan
8-K
CHRS
Coherus Biosciences Inc
13 Jan 22
Entry into a Material Definitive Agreement
4:39pm
required under antitrust laws with respect to such exercise by the Company of the license option for the TIGIT Program have expired or have been
8-K
fts0zq9e
22 Jan 24
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in Conference Call Information
8:01am
8-K
EX-2.1
sne m422c9ub6iz42x
22 Jan 24
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in Conference Call Information
8:01am
- Prev
- 1
- Next